373 related articles for article (PubMed ID: 23419412)
1. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
3. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
[TBL] [Abstract][Full Text] [Related]
4. Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Wadowski PP; Kopp CW; Koppensteiner R; Lang IM; Pultar J; Lee S; Weikert C; Panzer S; Gremmel T
Eur J Clin Invest; 2018 Jan; 48(1):. PubMed ID: 29171876
[TBL] [Abstract][Full Text] [Related]
5. Resistance to anti-platelet agents.
Cattaneo M
Thromb Res; 2011 Feb; 127 Suppl 3():S61-3. PubMed ID: 21262444
[TBL] [Abstract][Full Text] [Related]
6. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
7. Signaling via P2Y12 may be critical for early stabilization of platelet aggregates.
Speich HE; Bhal V; Houser KH; Caughran AT; Lands LT; Houng AK; Bäckstrom J; Enerbäck M; Reed GL; Jennings LK
J Cardiovasc Pharmacol; 2014 Jun; 63(6):520-7. PubMed ID: 24477045
[TBL] [Abstract][Full Text] [Related]
8. Ticagrelor effectively and reversibly blocks murine platelet P2Y12-mediated thrombosis and demonstrates a requirement for sustained P2Y12 inhibition to prevent subsequent neointima.
Patil SB; Jackman LE; Francis SE; Judge HM; Nylander S; Storey RF
Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2385-91. PubMed ID: 21071697
[TBL] [Abstract][Full Text] [Related]
9. Antiplatelet effect of clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions--limited inhibition of the P2Y12 receptor.
Lepäntalo A; Virtanen KS; Reséndiz JC; Mikkelsson J; Viiri LE; Karhunen PJ; Lassila R
Thromb Res; 2009 Jun; 124(2):193-8. PubMed ID: 19232433
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Gremmel T; Yanachkov IB; Yanachkova MI; Wright GE; Wider J; Undyala VV; Michelson AD; Frelinger AL; Przyklenk K
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):501-9. PubMed ID: 26743169
[TBL] [Abstract][Full Text] [Related]
11. Reversal strategy in antagonizing the P2Y12 -inhibitor ticagrelor.
Hobl EL; Derhaschnig U; Firbas C; Schoergenhofer C; Schwameis M; Jilma B
Eur J Clin Invest; 2013 Dec; 43(12):1258-61. PubMed ID: 24112116
[TBL] [Abstract][Full Text] [Related]
12. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
13. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R
Platelets; 2013; 24(4):297-302. PubMed ID: 22721490
[TBL] [Abstract][Full Text] [Related]
14. Advances in the monitoring of anti-P2Y12 therapy.
Harrison P
Platelets; 2012; 23(7):510-25. PubMed ID: 22916724
[TBL] [Abstract][Full Text] [Related]
15. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
16. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
17. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
18. Selective blockade of P2Y12 receptors by prasugrel inhibits myocardial infarction induced by thrombotic coronary artery occlusion in rats.
Sugidachi A; Yamaguchi S; Jakubowski JA; Ohno K; Tomizawa A; Hashimoto M; Niitsu Y
J Cardiovasc Pharmacol; 2011 Sep; 58(3):329-34. PubMed ID: 21697729
[TBL] [Abstract][Full Text] [Related]
19. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Steinhubl S; Roe MT
Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
[TBL] [Abstract][Full Text] [Related]
20. Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Dong Z; Zhai H; Pan L; Zhang B
J Pak Med Assoc; 2021 Feb; 71(2(A)):540-542. PubMed ID: 33819246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
